Evofem Biosciences Inc

OTCQB:EVFMUnited States

-- Financial Tables Follow --
EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands) As of ------------------------------- September 30, December 31, 2024 2023 --------------- -------------- Assets Current assets: Cash and cash equivalents $ - $ - Restricted cash 722 580 Trade accounts receivable, net 5,393 5,738 Total current liabilities 76,286 72,463 Total stockholders' deficit (70,888) (66,510) Total liabilities, convertible and redeemable preferred stock and stockholders' deficit $ 23,942 $ 10,554 EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share data) 2024 2023 2024 2023 ----------- ------------ ----------- ------------ Three Months Ended Nine Months Ended September 30, September 30, ------------------------- ------------------------- 2024 2023 2024 2023 ----------- ------------ ----------- ------------ Product sales, net $ 4,496 $ 5,112 $ 12,259 $ 13,379 Operating Expenses: Cost of goods sold 869 1,889 2,322 5,558 Amortization of intangible asset 301 - 301 - Research and development 332 614 1,196 1,556 Selling and marketing 2,382 2,985 6,970 9,036 General and administrative 3,052 3,176 8,143 11,696 ---------- ----------- ---------- ----------- Total operating expenses 6,936 8,664 18,932 27,846 ---------- ----------- ---------- ----------- Loss from operations (2,440) (3,552) (6,673) (14,467) Other income (expense): Interest income 3 2 13 28 Other income (expense), net (562) (596) (1,736) (2,041) Loss on issuance of financial instruments - (5,175) (3,300) (5,286) Gain (loss) on debt extinguishment (143) 75,337 977 75,337 Change in fair value of financial instruments 769 - 4,896 1,539 ---------- ----------- ---------- ----------- Total other income (expense), net 67 69,568 850 69,577 ---------- ----------- ---------- ----------- Income (loss) before income tax (2,373) 66,016 (5,823) 55,110 Income tax expense 8 (11) - (17) ---------- ----------- ---------- ----------- Net income (loss) (2,365) 66,005 (5,823) 55,093 ---------- ----------- ---------- ----------- Convertible preferred stock deemed dividends (5) - (99) - ---------- ----------- ---------- ----------- Net income (loss) attributable to common stockholders $ (2,370) $ 66,005 $ (5,922) $ 55,093 ========== =========== ========== =========== Net income (loss) per share attributable to common stockholders: Basic $ (0.02) $ 15.34 $ (0.09) $ 21.42 ========== =========== ========== =========== Diluted $ (0.02) $ 0.10 $ (0.09) $ 0.09 ========== =========== ========== =========== Weighted-average shares used to compute net income (loss) per share attributable to common shareholders: Basic 96,459,121 4,236,477 64,924,454 2,524,302 ========== =========== ========== =========== Diluted 96,459,121 729,979,486 64,924,454 694,561,898 ========== =========== ========== ===========

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024